Neuphoria Therapeutics (NEUP) Q4 2026 earnings summary

Executive summary

• Clinical-stage CNS biotech focused on allosteric ion channel modulators, with BNC210 as lead candidate for PTSD; all internal R&D paused pending strategic transaction.

• Entered into a merger agreement with Scancell Holdings plc; if completed, Neuphoria will become a subsidiary and Scancell does not plan to develop non-partnered assets.

• Major restructuring in FY26: terminated leases, reduced to one full-time employee, and shifted to external consultants; partners continue independent development of legacy and partnered programs.

Financial highlights

• Revenue for FY26 was $1.2M, down from $15.6M in FY25, reflecting the absence of a $15M Merck milestone received in FY25.

• Net loss for FY26 was $13.5M, compared to $0.4M in FY25; includes a $5.4M goodwill impairment due to Merck's termination of the MK-1167 Alzheimer's trial.

• Cash and cash equivalents at June 30, 2026 were $19.9M; working capital of $20.3M.

• Operating cash outflow was $12.4M in FY26, up from $0.1M in FY25, mainly due to lower milestone revenue and restructuring costs.

• No dividends declared or paid; all available funds retained for operations.

Outlook and guidance

• Existing cash expected to fund operations beyond Q2 FY28, assuming current cost structure and no resumption of R&D.

• Future development of BNC210 or other assets contingent on additional financing or third-party partnership; Scancell does not intend to develop non-partnered assets post-merger.

• If merger fails, company may seek alternative strategic transactions or consider liquidation.